All Studies Meta Analysis

Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients

Chachar et al., International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378

Sep 2020

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 112 treatments. c19ivm.org

Small RCT with 25 ivermectin and 25 control patients, not finding a significant difference in recovery at day 7.

This is the 5th of 52 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000021.

This is the 9th of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).

Important missing comments or errors? Let us know.

risk of no recovery at day 7, 10.0% lower, RR 0.90, p = 0.50, treatment 9 of 25 (36.0%), control 10 of 25 (40.0%), NNT 25, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Chachar et al., 30 Sep 2020, Randomized Controlled Trial, India, peer-reviewed, 6 authors, dosage 36mg, 12mg stat, 12mg after 12 hours, 12mg after 24 hours.

This Paper Ivermectin All

Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients

Aijaz Zeeshan Khan Chachar, Khurshid Ahmad Khan, Mohsin Asif, Khushbakht Tanveer, Arous Khaqan, Rabia Basri

International Journal of Sciences, doi:10.18483/ijsci.2378

Background:The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into a global pandemic. Objectives: To assess the efficacy of Ivermectin in mild cases of COVID-19 patients on the basis of predefined assessment criteria. Study Settings: Fatima Memorial Hospital, Lahore Study Design: Open label randomized control trial. Duration of Study: From 1 st May, 2020 to 30 th June, 2020.Patients & Methods: Sample size and technique: Sample size was 50 patients; 25 patients were kept in control group and 25 patients were kept in experimental group. Results: There were total 50 patients, divided into two groups case and control group.The mean age of the participants was 40.60 ± 17 and out of those 31 (62%) were male and 19 (38%) were females. Cough was observed more in case group (p= 0.049). Fever, myalgias and dyspnea were the commonest symptoms in both the groups (p= 1.000). Diarrhea and vomiting were more common in control group (p=0.0001, p= 0.042 respectively). On follow up at day 7, patients were stratified as asymptomatic and symptomatic. Amongst the case group, out of 25 patients, 16(64%) patients were asymptomatic and rest of the 9(36%) patients was asymptomatic. In control group, out of 25 patients, 15(60%) patients were asymptomatic and rest of the 10(40%) patients was asymptomatic. p-value (0.500). Statistically there was no significant difference between case group who were given ivermectin along with symptomatic treatment and control group who were only given symptomatic treatment without ivermectin, being asymptomatic on day 7 at follow up. p-value (0.500

References

Bai, Yao, Wei, Tian, Jin et al., Presumed asymptomatic carrier transmission of COVID-19, Jama, doi:10.1001/jama.2020.2565

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral research, doi:10.1016/j.antiviral.2020.104787

Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients, doi:10.21203/rs.3.rs-38896/v1

David, What is the role of antiparasitic drug ivermectin in the treatment of corona virus disease, doi:10.26434/chemrxiv.11875446.v1

Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, The Journal of Antibiotics, doi:10.1038/s41429-020-0336-z

Lu, Stratton, Tang, Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle, Journal of medical virology, doi:10.1002/jmv.25678

Patel, Usefulness of Ivermectin in COVID-19 Illness, doi:10.1101/2020.06.06.20124461

Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19, medRxiv, doi:10.26434/chemrxiv.11875446.v1

Sohrabi, Alsafi, Neill, Khan, Kerwan et al., World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), International Journal of Surgery, doi:10.1016/j.ijsu.2020.03.036

Yavuz, Ünal, Antiviral treatment of COVID-19, Turkish Journal of Medical Sciences, doi:10.3906/sag-2004-145

{ 'indexed': {'date-parts': [[2024, 3, 8]], 'date-time': '2024-03-08T12:31:16Z', 'timestamp': 1709901076463}, 'reference-count': 0, 'publisher': 'Alkhaer Publications', 'issue': '09', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.18483/ijsci.2378', 'type': 'journal-article', 'created': {'date-parts': [[2020, 10, 9]], 'date-time': '2020-10-09T03:28:22Z', 'timestamp': 1602214102000}, 'page': '31-35', 'source': 'Crossref', 'is-referenced-by-count': 19, 'title': 'Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients', 'prefix': '10.18483', 'volume': '9', 'author': [ {'given': 'Aijaz', 'family': 'Zeeshan Khan Chachar', 'sequence': 'first', 'affiliation': []}, {'given': 'Khurshid', 'family': 'Ahmad Khan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohsin', 'family': 'Asif', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khushbakht', 'family': 'Tanveer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arous', 'family': 'Khaqan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rabia', 'family': 'Basri', 'sequence': 'additional', 'affiliation': []}], 'member': '7748', 'published-online': {'date-parts': [[2020]]}, 'container-title': 'International Journal of Sciences', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2020, 10, 9]], 'date-time': '2020-10-09T03:28:23Z', 'timestamp': 1602214103000}, 'score': 1, 'resource': {'primary': {'URL': 'http://www.ijsciences.com/pub/article/2378'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020]]}, 'references-count': 0, 'journal-issue': {'issue': '09', 'published-online': {'date-parts': [[2020]]}}, 'alternative-id': ['92020092378'], 'URL': 'http://dx.doi.org/10.18483/ijSci.2378', 'relation': {}, 'ISSN': ['2305-3925', '2410-4477'], 'subject': ['General Materials Science'], 'container-title-short': 'ijSciences', 'published': {'date-parts': [[2020]]}}

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0